Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives
SE Rebuzzi, R Alfieri, S La Monica, R Minari… - Critical Reviews in …, 2020 - Elsevier
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improved clinical
outcome compared to chemotherapy in EGFR mutated advanced non-small cell lung cancer …
outcome compared to chemotherapy in EGFR mutated advanced non-small cell lung cancer …
[HTML][HTML] Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint
E Rulli, F Ghilotti, E Biagioli, L Porcu… - British journal of …, 2018 - nature.com
Background The evaluation of the proportional hazards (PH) assumption in survival analysis
is an important issue when Hazard Ratio (HR) is chosen as summary measure. The aim is to …
is an important issue when Hazard Ratio (HR) is chosen as summary measure. The aim is to …
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study,
showed that intercalated chemotherapy and erlotinib significantly prolonged progression …
showed that intercalated chemotherapy and erlotinib significantly prolonged progression …
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta …
Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic …
PM Ellis, N Coakley, R Feld, S Kuruvilla, YC Ung - Current oncology, 2015 - mdpi.com
Introduction: This systematic review addresses the use of epidermal growth factor receptor
(egfr) inhibitors in three populations of advanced non-small-cell lung cancer (nsclc) patients …
(egfr) inhibitors in three populations of advanced non-small-cell lung cancer (nsclc) patients …
[HTML][HTML] Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC
W Peng, C Yao, Q Pan, Z Zhang, J Ye, B Shen… - Frontiers in …, 2023 - frontiersin.org
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) represented by
gefitinib and erlotinib are widely used in treating non-small cell lung cancer (NSCLC) …
gefitinib and erlotinib are widely used in treating non-small cell lung cancer (NSCLC) …
[HTML][HTML] Incremental innovation and progress in advanced squamous cell lung cancer: current status and future impact of treatment
CJ Langer, C Obasaju, P Bunn, P Bonomi… - Journal of Thoracic …, 2016 - Elsevier
Squamous cell lung cancer (sqCLC) is an aggressive form of cancer that poses many
therapeutic challenges. Patients tend to be older, present at a later stage, and have a high …
therapeutic challenges. Patients tend to be older, present at a later stage, and have a high …
[HTML][HTML] Lung cancer in the Netherlands
LEL Hendriks, AMC Dingemans… - Journal of Thoracic …, 2021 - Elsevier
Disclosure: Dr. Hendriks reports no conflict of interest related to the current manuscript.
Outside of the current manuscript, Dr. Hendriks reports receiving research funding from …
Outside of the current manuscript, Dr. Hendriks reports receiving research funding from …
[HTML][HTML] Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis
AD Vickers, KB Winfree, G Cuyun Carter, U Kiiskinen… - BMC cancer, 2019 - Springer
Background Locally advanced or metastatic non-small cell lung cancer (NSCLC) that has
progressed after first-line treatment has a poor prognosis. Recent randomized clinical trials …
progressed after first-line treatment has a poor prognosis. Recent randomized clinical trials …
High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases—one with a remarkable thoracic response as well
JL Kuiper, EF Smit - Lung cancer, 2013 - Elsevier
A considerable number of patients with epidermal growth factor receptor (EGFR)-mutated
non-small-cell lung cancer (NSCLC) develop leptomeningeal metastases. Leptomeningeal …
non-small-cell lung cancer (NSCLC) develop leptomeningeal metastases. Leptomeningeal …